ArticleObesity (Silver Spring, Md.)2016
Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s.
Article in Obesity (Silver Spring, Md.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pharmacogenetic interactions of medications administered for weight loss in adults: a systematic review and meta-analysis.Pharmacogenomics · 2023Pooled it
- Pooled it
- A Randomized, Double-Blind, Placebo-Controlled Study of Gelesis100: A Novel Nonsystemic Oral Hydrogel for Weight Loss.Obesity (Silver Spring, Md.) · 2019Trial
- Article
- The Economic Cost of Obesity: A Cost-of-Illness Study in Greece.Applied health economics and health policy · 2026Article
- Obesity and obstructive sleep apnea: from pathophysiology to current clinical approaches.Respiratory research & clinical practice · 2026Review
- Socio-demographic and clinical factors associated with the receipt of anti-obesity medication prescriptions and metabolic and bariatric surgery among eligible all of Us participants.Diabetes, obesity & metabolism · 2025Article
- Metformin and weight loss medication impact on survival outcomes in older women with obesity-related cancers.Scientific reports · 2025Article
- Perceptions of anti-obesity medications among people with obesity and healthcare providers in the US: Findings from the OBSERVE Study.Obesity (Silver Spring, Md.) · 2025Observational
- Regional trends and disparities in newer GLP1 receptor agonist initiation among real-world adult patients eligible for obesity treatment.Diabetes, obesity & metabolism · 2025Article
- Determinants of adherence to obesity medication: A narrative review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025Review
- Leveraging diagnosis and biometric data from the All of Us Research Program to uncover disparities in obesity diagnosis.Obesity pillars · 2025Article
- Perceptions of Obesity Among Healthcare Professionals and Policy Makers in 2023: Results of the Global OPEN Survey.Obesity science & practice · 2025Article
- Contemporary treatment patterns of overweight and obesity: insights from the Mass General Brigham health care system.Obesity (Silver Spring, Md.) · 2025Article
- Factors Associated With Semaglutide Initiation Among Adults With Obesity.JAMA network open · 2025 · on this mapObservational
- Spending, utilization, and price trends for anti-obesity medications in U.S. Medicaid programs: an empirical analysis from 1999 to 2023.Frontiers in medicine · 2025Article
- The Burden of Obesity in Saudi Arabia: A Real-World Cost-of-Illness Study.ClinicoEconomics and outcomes research : CEOR · 2025Article
- Evolving Approaches for Pharmacological Therapy of Obesity.Annual review of pharmacology and toxicology · 2025Review
- Effectiveness and predictors of weight loss response to phentermine plus lifestyle modifications among youth in a paediatric weight management clinical setting.Pediatric obesity · 2024Article
- Association of patient characteristics and insurance type with anti-obesity medications prescribing and fills.Diabetes, obesity & metabolism · 2024Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
Abstract
objectiveTo characterize the adoption of antiobesity pharmacotherapies, as compared with that of the newest antidiabetes pharmacotherapy, subtype 2 sodium-glucose transport protein inhibitors (SGLT2s), among prescribers in the United States.
methodsA retrospective analysis of 2012 to 2015 data extracted from the IMS Health National Prescription Audit™ and Xponent™ assessed adoption rates of antiobesity pharmacotherapies and SGLT2s.
resultsThe number of dispensed antidiabetes prescriptions was 15 times the number of dispensed antiobesity prescriptions. The antiobesity market share was: 74.0% phentermine, 18.6% new antiobesity pharmacotherapies. The mean increase in prescriptions/month were: 25,259 for SGLT2s, 5,154 for new antiobesity pharmacotherapies, and 2,718 for phentermine. Medical specialties prescribing the majority of the analysis medications were Family Medicine/General Practice and Internal Medicine. Endocrinology had the highest prevalence of prescribers of any subspecialty.
conclusionsThe adoption rate of SGLT2s was nearly exponential, while the adoption rate of new antiobesity pharmacotherapies was linear. Considering the relative prevalence of obesity to diabetes and that obesity is a major cause of diabetes, these results are paradoxical and suggest systematic barriers against the prescribing of antiobesity pharmacotherapies. The under-prescribing of antiobesity pharmacotherapies is widely acknowledged, but this is the first prescription data of these new medications to demonstrate its extent in the United States.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.